SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Nectar Lifesciences - Quaterly Results

31 Jan 2025 Evaluate
A minor change in the total revenue was seen in the December 2024 quarter. The total revenue for the quarter stood at Rs. 4549.82 millions against Rs. 4521.71 millions during year ago period.The company almost doubled its revenue to Rs. 78.40 millions  from Rs. 15.65 millions in the quarter ended December 2024.OP of the company witnessed a marginal growth to 452.83 millions from 426.70 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 4549.82 4521.71 0.62 12423.80 12442.56 -0.15 16856.32 15246.09 10.56
Other Income 5.73 4.80 19.38 18.13 115.61 -84.32 130.30 422.39 -69.15
PBIDT 452.83 426.70 6.12 1296.59 1161.57 11.62 1661.35 979.02 69.70
Interest 171.22 248.41 -31.07 569.07 629.83 -9.65 871.42 794.76 9.65
PBDT 281.61 178.29 57.95 727.52 531.74 36.82 789.93 184.26 328.70
Depreciation 156.14 153.74 1.56 466.23 460.18 1.31 607.18 591.19 2.70
PBT 125.47 24.55 411.08 261.29 71.56 265.13 182.75 -406.93 -144.91
TAX 47.07 8.90 428.88 97.22 27.54 253.01 132.74 -182.37 -172.79
Deferred Tax 47.07 8.90 428.88 97.22 27.54 253.01 132.74 -182.37 -172.79
PAT 78.40 15.65 400.96 164.07 44.02 272.72 50.01 -224.56 -122.27
Equity 224.26 224.26 0.00 224.26 224.26 0.00 224.26 224.26 0.00
PBIDTM(%) 8.97 8.31 7.96 10.44 9.34 11.79 8.62 5.60 53.86

Nectar Lifesciences Share Price

12.63 0.22 (1.77%)
17-Apr-2026 13:10 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.70
Dr. Reddys Lab 1228.80
Cipla 1233.40
Zydus Lifesciences 944.80
Lupin 2305.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×